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Endothelial cell rearrangements during vascular
patterning require PI3-kinase-mediated inhibition
of actomyosin contractility
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Angiogenesis is a dynamic process relying on endothelial cell rearrangements within vascular
tubes, yet the underlying mechanisms and functional relevance are poorly understood. Here
we show that PI3Kα regulates endothelial cell rearrangements using a combination of a
PI3Kα-selective inhibitor and endothelial-specific genetic deletion to abrogate PI3Kα activity
during vessel development. Quantitative phosphoproteomics together with detailed cell
biology analyses in vivo and in vitro reveal that PI3K signalling prevents NUAK1-dependent
phosphorylation of the myosin phosphatase targeting-1 (MYPT1) protein, thereby allowing
myosin light chain phosphatase (MLCP) activity and ultimately downregulating actomyosin
contractility. Decreased PI3K activity enhances actomyosin contractility and impairs junc-
tional remodelling and stabilization. This leads to overstretched endothelial cells that fail to
anastomose properly and form aberrant superimposed layers within the vasculature. Our
findings define the PI3K/NUAK1/MYPT1/MLCP axis as a critical pathway to regulate acto-
myosin contractility in endothelial cells, supporting vascular patterning and expansion
through the control of cell rearrangement.
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T issue growth and homoeostasis require the establishmentof a functional hierarchical tubular network of blood ves-sels1. Blood vessels are mainly formed by a process known
as sprouting angiogenesis in which new vascular sprouts arise
from parental vessels, grow, and fuse to an adjacent sprout or a
pre-existing vessel1,2. Newly formed sprouts are highly dynamic
with endothelial cells interchanging their relative position within
the vascular tube3–7. This collective cell migration across the
vascular tubes relies on cell rearrangement; yet the regulation of
this cell behaviour during the formation and patterning of blood
vessels is poorly understood.
Endothelial cell rearrangement occurs through the reorgani-
zation of cell–cell junctional contacts thereby allowing the mod-
ification of cell−cell adhesion strengths7–10. In endothelial cells,
there are two types of vascular endothelial-cadherin (Cdh5/VE-
cadherin)-based junctional patterns, namely continuous or
straight, and discontinuous or serrated7,9,10. Straight junctional
VE-cadherin organization is mainly found in stable and mature
junctions, whereas the serrated VE-cadherin junctional pattern is
considered as immature or remodelling junctions9,10. Although
these VE-cadherin junctional patterns are not visible in the
endothelium during zebrafish developmental angiogenesis11,
computational models have proposed that spatial heterogeneity of
these junctional patterns is necessary for cells to rearrange
in vivo7. Yet, how these junctional profiles impact on the capacity
of endothelial cells to rearrange remains poorly understood.
Formation, remodelling, and stabilization of cell−cell adhesions
in cultured endothelial cells are mediated by actin structures12.
At mature junctions, linear VE-cadherin is aligned to parallel
cortical actin bundles. Instead, serrated immature junctions
are connected to perpendicular or radial tensile actin cables9,10.
The switch between stable and immature junctions is mediated
by actomyosin contraction-based pulling forces at the cell–cell
junctions9,10,13.
Among the different players of the angiogenic process, class I
PI3-kinases (PI3K) have emerged as a critical node14, for
both the physiology of endothelial cells15,16 and the pathogenesis
of venous malformations17,18, the most common type of vascular
malformations. PI3Ks are lipid kinases that signal downstream
of a variety of cell surface receptors and regulate cellular functions
including growth, proliferation, migration, and metabolism19.
Upon activation, these enzymes generate the lipid phosphatidly-
linositiol-3,4,5-triphosphate, a second messenger that triggers
signalling pathways, such as those mediated by the serine/
threonine kinase AKT and its substrates20. Of the class I PI3K
isoforms, PI3Kα has been shown to be the only isoform required
for endothelial-mediated vascular development15. Several studies
have demonstrated that PI3Kα signalling primary regulates
cell motility during angiogenesis in mouse and zebrafish15,21,22.
Our study uncovers a PI3K downstream pathway, namely
NUAK1/MYPT1/MLCP, as a critical node in the regulation of
cell rearrangement during vessel growth. We have found that
blockade of PI3Kα signalling impairs junctional remodelling, inhi-
bits cell rearrangement and drives endothelial cells to grow in
superimposed aberrant layers. We identify that a failure of cells to
rearrange results in cell stretching and inability to remodel and
stabilize new cell–cell contacts upon anastomosis. Through a
combination of in vivo and in vitro approaches together with an
unbiased and deep quantitative phosphoproteomic screening, we
have discovered that PI3Kα mediates cell rearrangement by inhi-
biting actomyosin contractility through NUAK1/MYPT1/MLCP.
Results
PI3Kα mediates rearrangement of endothelial cells. Here, we
investigated how endothelial cell rearrangements within the
vascular sprouts contribute to vessel expansion and patterning.
We and others have shown that the PI3Kα isoform regulates
endothelial cell motility (Supplementary Fig. 1, Supplementary
Movies 1 and 2, and refs. 15,21,22). Therefore, we predicted that
cell rearrangement would be altered upon blockage of this
signalling node. To validate our hypothesis, we first studied
vessel growth in zebrafish embryos treated with a PI3Kα
isoform-specific inhibitor (GDC-0326; ref. 23). We focused
our studies between 27 and 38 h post fertilization (hpf), when
intersegmental vessels (ISVs) that arise from the dorsal aorta
reach the dorsal roof and form the dorsal longitudinal anasto-
motic vessels (DLAVs)24. Treatment with GDC-0326 efficiently
inhibited PI3K signalling (Supplementary Fig. 2a) and this
led to aberrant endothelial cell junctional patterns. Junctions
were frequently disconnected in the dorsal region of the ISV
axis and the junctional elongation was reduced in both ISVs
and DLAV (Fig. 1a, b). We also observed the presence of ring-
shaped junctions in these embryos that suggests lack of
tight contact between adjacent endothelial cells (Fig. 1a). More-
over, GDC-0326-treated embryos showed a delay in the growth
of ISVs (Supplementary Fig. 2b-d), without an overall delay in
embryo development (Supplementary Fig. 2e). These aberrant
junctional patterns are indicative of defects in cell rearrange-
ments11. Conversely, in vehicle-treated embryos, ISV outgrowth
was accompanied by a normal extensive junctional remodelling
leading to a pattern of highly elongated endothelial cell junctions
(Fig. 1a, b).
In order to translate our observations into a mammalian
model, we inactivated PI3Kα in endothelial cells using genetic
approaches and we studied retinal angiogenesis. To maximize
Pik3ca deletion and avoid compensations by other PI3K isoforms
we studied Pik3caKD/flox mice, in which one Pik3ca allele is a
constitutive kinase-dead (KD)25, and the other is a lox-P-flanked
Pik3ca allele15. Pik3caKD/flox mice were crossed into the Pdgfb-
iCreER transgenic mouse, which expresses a tamoxifen-inducible
CRE recombinase specifically in endothelial cells26 (further
referred to as Pik3caKD/iΔEC) (Supplementary Table 1 provides
details of the mouse models used). To ensure that Pik3ca flox
allele is completely knocked out in our experimental settings,
we assessed PI3Kα half-life in Pik3caflox/flox mice crossed
into the Pdgfb-iCreER (referred to as Pik3caiΔEC/iΔEC). Complete
depletion of the PI3Kα protein was achieved at 96 h after 4-
hydroxytamoxifen (4-OHT) treatment (Supplementary Fig. 3a).
Thus, to reach complete PI3Kα depletion in vivo, we adminis-
tered 4-OHT at postnatal day (P) 1 and P2 and investigated
Pik3caKD/iΔEC retinas at P7. As compared to control retinas,
Pik3caKD/iΔEC P7 retinas showed a decrease in phospho-S6 (pS6)
(S240/4) and an enhanced nuclear FOXO1 staining confirming
the inactivation of the PI3K pathway (Supplementary Fig. 3b, c).
In line with our previous findings in zebrafish embryos, we
observed that endothelial cells in Pik3caKD/iΔEC retinas showed an
increased number of junctional gaps (Fig. 1c–e; yellow arrow-
heads). Furthermore, in a proportion of vascular tubes, the
junction gaps resulted either in isolated rings or single-dots of
VE-cadherin, indicating lack of tight contacts between endothelial
cells (Fig. 1c; red asterisks). To investigate this phenotype in
further detail, we analysed VE-cadherin-based cell−cell junctions
in cultured endothelial cells from Pik3caKD/iΔEC mice by
immunostaining for β-catenin and F-actin (Fig. 1f). These
experiments showed that Pik3caKD/iΔEC endothelial cells failed
to establish mature cell−cell junctions; instead, most of the
junctions remained immature and connected to radial actin
fibres (Fig. 1f–h). Together these data indicate that PI3Kα
signalling is involved in cell−cell junctional remodelling in
endothelial cells, a process required for cellular rearrangements
within the vasculature.
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Defects in cell rearrangements lead to anastomosis failure. P7
Pik3caKD/iΔEC retinas exhibited a significant reduction in vascular
radial outgrowth (Fig. 2a and Supplementary Fig. 4a) with no
detectable differences in sprouting activity (Supplementary
Fig. 4c, d). This phenotype was further increased at P10, with the
sprouting front of Pik3caKD/iΔEC retinas neither reaching the
periphery of the retina nor invading deeper retinal layers (Fig. 2a
and Supplementary Fig. 4b). However, P7 Pik3caKD/iΔEC retinas
showed an increase in vessel density with vascular tubes growing
in multiple layers (Fig. 2a–c; Supplementary Fig. 4e and
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Supplementary Movies 3 and 4); this superposition was more
pronounced at P10 (Supplementary Fig. 4b, f). Also, the vascular
tubes in Pik3caKD/iΔEC retinas showed smaller calibre (Fig. 2b, c).
Analysis of Pik3caKD/WT and Pik3caiΔEC/iΔEC retinas (Supple-
mentary Table 1) showed that the former appeared normal,
whereas Pik3caiΔEC/iΔEC retinas looked similar to Pik3caKD/iΔEC
retinas but with milder vascular defects (Supplementary Fig. 4a,
b).
Current models of enhanced vessel density involve an increase
in the number of endothelial cells16,17,27,28. However, immunos-
taining of endothelial cell nuclei revealed a significant reduction
in the total number of endothelial cells (Fig. 3a, b) and in
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Fig. 2 Endothelial PI3Kα regulates vascular growth. a Representative images of whole mount retinas stained with IB4 from control and Pik3caKD/iΔEC mouse
littermates at P7 and at P10. Veins (V) and arteries (A) are indicated. White arrowheads show areas where the vascular plexus is superimposed.
b Representative high-magnification images of whole mount retinas stained with IB4 from control and Pik3caKD/iΔEC mouse littermates at P7. Two
independent areas for Pik3caKD/iΔEC retinas are shown. White islets show higher magnification of selected regions shown below. c Quantification of number
of branch points per unit area and vessel width per unit area of control (Ctrl) and Pik3caKD/iΔEC (Pik3ca) retinas (n≥ 6 retinas per genotype). Scale bars,
100 µm (a), 20 µm (b, upper panels), 10 µm (b, lower panels). Data represent mean ± SEM (error bars). ***P < 0.001. Statistical analysis was performed by
the two-sided Mann–Whitney test
Fig. 1 Defects in junctional remodelling upon inactivation of PI3Kα in endothelial cells. a Lateral views of intersomitic vessels (ISV) in vehicle and GDC-
0326 (50 μM)-treated transgenic Tg(kdrl:EGFP)s843 (shown in red) embryos stained for ZO-1 (green) at 33 h post fertilization (hpf). Single ZO-1 staining is
shown in upper row. DA refers to dorsal aorta and DLAV refers to dorsal longitudinal anastomotic vessels. White lines indicate ZO-1 negative staining;
punctuate white lines indicate elongation of junction; yellow arrowheads show ring-shape junctions. b Quantification of the length of the dorsal part of the
ISVs without ZO-1 (left graph) and length of the ISVs with continuous ZO-1 staining (right graph) in vehicle and GDC-0326 treated embryos (n≥ 54 ISVs
per treatment). c Representative maximum intensity projections of anti-VE-cadherin (green) and isolectin B4 (IB4, red) immunostained control and
Pik3caKD/iΔEC mouse retinas at P7. Single channel is shown in upper row. Yellow islets show higher magnification of selected regions shown to the right.
Yellow arrowheads indicate vascular segments without VE-cadherin staining; red asterisks indicate VE-cadherin-positive isolated rings or single-dots within
the vascular tubes, indicating cell−cell junctional contacts that have not elongated. d, e Quantitative number of VE-cadherin-negative vessels (junctional
gaps) per unit area (n≥ 5 retinas per genotype) (d) and length of vessel structures without VE-cadherin (length of junctional gaps) (n≥ 6 retinas per
genotype) (e). f Confocal immunofluorescence images of primary mouse endothelial cells isolated from control and Pik3caKD/iΔEC mice stained for β-
catenin (green) and F-actin (red) after being treated with 4-OHT for 72 h and re-plated on gelatin-coated slides for 24 h. Yellow arrowheads indicate
straight junctional pattern; orange arrowheads indicate serrated junctional pattern. g Graph shows the average of β-catenin-positive area along junctional
linescans (n≥ 109 cells from six independent experiments). h Quantification of percentages of cells with serrated, straight or mixed junctions (n= 5
independent experiments). Scale bars, 30 µm (a), 20 µm (c), 10 µm (c small panel, f). Data in b, d, e, g, h represent mean ± SEM (error bars). *P < 0.05, **P
< 0.01, ****P < 0.0001 were considered statistically significant. Statistical analysis was performed by the two-sided Mann–Whitney test
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endothelial cells in S-phase in Pik3caKD/iΔEC retinas (Supple-
mentary Fig. 5a, b). Endothelial cells were highly stretched in
Pik3caKD/iΔEC retinal vessels, with the distance between adjacent
endothelial cell nuclei increased by twofold (Fig. 3a, b).
This suggests that these cells failed to elongate alongside
each other, a process known as cell pairing29, and as a
consequence the cells overstretched. Given the lower number
of endothelial cells in GDC-0326-treated embryos and in
Pik3caKD/iΔEC retinas, a reduction in cell number might
interfere with cell rearrangement during sprouting angiogenesis
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(as shown in Fig. 1). To test this possibility, we inhibited cell
proliferation with systemic administration of mitomycin C at P5,
48 h before harvesting the retinas at P7, followed by assessing cell
proliferation and vascular patterning. As previously described30,
5-ethynyl-2′-deoxyuridine (EdU) incorporation showed a promi-
nent block in endothelial cell proliferation in mitomycin C-
treated retinas, leading to an overall reduction in endothelial cells
(Supplementary Fig. 5c-f). However, no major differences in VE-
cadherin junctional pattern were observed (Supplementary Fig. 5e,
f). Similar results were observed in zebrafish embryos upon
administration of the cell cycle blockers aphidicolin (APH) or
hydroxyurea (HU) (Supplementary Fig. 6a-g). These data indicate
that inhibition of cell proliferation per se does not impair cell
rearrangement.
We hypothesized that the increase in vascular branches
observed in Pik3caKD/iΔEC retinas (Fig. 2b, c) was the result of
stretched endothelial cells extending multiple protrusions. To
visualize single-cell morphology, we used R26-mTmG reporter
mice, which express a membrane-bound green fluorescent
protein (GFP) upon Cre recombination31. We crossed R26-
mTmG reporter mice with Pik3caKD/iΔEC mice and reduced the
tamoxifen dose in order to induce mosaic inactivation of PI3Kα
(Supplementary Fig. 7a). Analysis of single cells confirmed
stretched cell-shapes upon inactivation of PI3Kα (Fig. 3c, d). Cell
pairing is an important process for the formation of multicellular
vascular tubes; thus the absence of cell pairing might result in
defects in lumen formation. Staining for intracellular adhesion
molecule 2 (ICAM2), a marker of the apical side of vessels,
confirmed frequent lumenal gaps in Pik3caKD/iΔEC retinal vessels.
The lack of ICAM2 staining in Pik3caKD/iΔEC retinas was
principally observed in thin tubular structures (Supplementary
Fig. 7b, c; yellow asterisks), supporting the notion that the
nonluminized tubes are only cell protrusions. Inactivation of
PI3Kα also led to an increase in collagen IV empty sleeves in
newly formed sprout connections (Fig. 3e, f), showing a lack of
stabilization of new contacts and a failure to anastomose. In
zebrafish embryos treated with GDC-0326, time-lapse analysis of
DLAV formation confirmed that initial contacts between adjacent
sprouts occurred but they failed to stabilize, resulting in frequent
cell retraction and sprout disconnections (Fig. 3g; Supplementary
Movies 5 and 6).
Together, our data show that PI3Kα is necessary for cells to
rearrange by regulating remodelling, elongation and stabilization
of junctional contacts. Lack of cell rearrangements results in
stretched endothelial cells which extend multiple protrusions that
fail to anastomose and grow in superimposed aberrant layers
(Fig. 3h). While proliferation defects likely contribute to impaired
cell rearrangement upon inhibition of PI3K, our data indicate that
PI3K signalling primarily regulates junctional remodelling and
cell rearrangement.
PI3Kα inhibition upregulates phospho-MYPT1. To define the
molecular and signalling changes occurring upon inactivation
of PI3Kα in endothelial cells, we performed untargeted mass
spectrometry (MS)-based phosphoproteomics analyses in pri-
mary mouse endothelial cells from Pik3caflox/flox (control) and
Pik3caKD/iΔEC mice. We analysed four biological replicates
per genotype, each of which was treated with vehicle (ethanol)
for 24 h or 4-OHT for 24 and 96 h (Fig. 4a). We identified
a total of 6836 phosphopeptides in the 24 samples analysed,
which were quantified using a previously described label-free
methodology32, generating 328,128 data points. This analysis
identified: (i) 224 differently regulated phosphopeptides in
the Pik3caKD/flox endothelial cells relative to control; (ii) 122
deregulated phosphopeptides in Pik3caKD/iΔEC endothelial cells
upon 24 h treatment with 4-OHT; and (iii) 202 deregulated
phosphopeptides in Pik3caKD/iΔEC endothelial cells upon 96 h
treatment with 4-OHT (Fig. 4b, c).
We clustered the phosphorylation sites that were significantly
deregulated at 96 h post 4-OHT treatment by gene ontology
(Supplementary Fig. 3a). Of particular relevance for the cell
rearrangement phenotype observed, we found a total of 23
phosphosites from 14 cytoskeleton-related proteins that were
differently modulated between Pik3caKD/iΔEC and control
endothelial cells. These included the myosin light chain
phosphatase (MLCP), CDC42, RAC1, junctional proteins, focal
adhesions, intermediate filaments, and microtubules (Fig. 4d).
Among the different candidates, Pik3caKD/iΔEC endothelial
cells showed an upregulation on the S445 phosphosite (pS445) of
the phosphatase 1 regulatory subunit 12 A (Ppp1r12A) also
known as MYPT1 (Fig. 4d). This protein was of particular
interest because, together with PP1β and M20, it composes the
MLCP complex and regulates the dephosphorylation of the
myosin light-chain (MLC) 2 (refs. 33–36), which is required for
the contraction of actomyosin (illustration is shown in Supple-
mentary Fig. 8a). We validated the increase of pS445 MYPT1
in Pik3caKD/iΔEC endothelial cells by western blot (Fig. 4e;
Supplementary Fig. 8b, c). Also, we confirmed the PI3Kα-
mediated regulation of pS445 MYPT1 in wild-type endothelial
and HEK-293 cells treated with GDC-0326 (Fig. 4e; Supplemen-
tary Fig. 8b, c).
Fig. 3 Cell stretching defects and anastomosis failure in Pik3caKD/iΔEC vessels. a Representative images of retinas stained for ERG (green) and IB4 (red)
from control and Pik3caKD/iΔEC P7 pups. Higher magnification are shown to the right. b Quantification of endothelial cells per unit area assessed by ERG
positivity and of the distance between two adjacent endothelial cell nuclei (n≥ 6 retinas per genotype). c Immunostaining of single-cell labelling with
membrane-bound GFP (mGFP, blue), endothelial nuclei (ERG, green) and blood vessel (IB4, red). Retinas from Pdgfb-iCre;Pik3caWT/flox were used as
control. d Quantification of cell size of individual mGFP-positive cells in control and Pik3caKD/iΔEC retinas. At least 89 individual mGFP-positive cells from
four independent retinas per genotype were quantified. e Images of control and Pik3caKD/iΔEC P7 retinas stained for collagen IV (green) and IB4 (red).
Single channels are also shown. White punctuated islet in the image of a Pik3caKD/iΔEC retina shows higher magnification of selected region to the right. Red
arrowheads indicate a retracting sprout. f Quantification of retracting sprouts per area (n= 4 retinas per genotype). g Images from a time-lapse movie
(starting at 30 hpf) showing lateral views of ISV morphogenesis in transgenic Tg(UAS:EGFP-UCHD)ubs18;(kdrl:mCherry-CAAX)S916 embryos treated with
vehicle (left panel) or GDC-0326 (50 μM) (right panel). Endothelial cell membrane is visualized in red and the actin cytoskeleton is visualized by F-actin
binding domain of utrophin in green. Single channels are also shown. Red arrow shows a retracting event between two endothelial cells. h Schematic
illustration showing the vascular defects driven by inactivation of PI3Kα (designed by Ana Angulo-Urarte). During vessel growth remodelling, stabilization,
and elongation (punctuated arrow) of adherent junctional contacts is required between neighbouring endothelial cells to rearrange. Upon inactivation of
PI3Kα, endothelial cells fail to stabilize (black arrow) and elongate (crossed punctuated arrow) junctional contacts. Scale bars, 40 µm (a), 20 µm (a
amplified panels, e), 10 µm (c, e amplified panels) 15 µm (g). Data in b, d, and f represent mean ± SEM (error bars). *P < 0.05, **P < 0.01, ***P < 0.001.
Statistical analysis was performed by the two-sided Mann−Whitney test
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PI3Kα is required to suppress actomyosin contractility.
Zagoroska et al. found that S445 MYPT1 phosphorylation trig-
gers the binding of MYPT1 to 14-3-3, thereby blocking the ability
of the MLCP complex to dephosphorylate MLC2 in S19 and T18/
S19 (ref. 35). Thus, we predicted that inhibition of PI3Kα, and the
resultant increase of MYPT1 S445 phosphorylation, might pro-
mote the detachment of MLCP from the actomyosin machinery,
thereby increasing actomyosin contractility. Indeed, we detected
that the ability of MYPT1 to bind β-actin in an overlay assay was
reduced upon inhibition of PI3Kα (Fig. 5a). By knocking down
MYPT1 protein expression with small interference RNA (siRNA),
we found that phosphorylation of MLC2 at S20 (S19 in humans)
was increased upon MYPT1 downregulation in endothelial cells
(Fig. 5b–d).
Enhanced phosphorylation of MLC2 on S20 was also found
upon both genetic and pharmacologic inhibition of PI3Kα in
mouse endothelial cells (Supplementary Fig. 9a, b). Moreover,
pS20 MLC2 staining was enriched at the subcortical region of
Pik3caKD/iΔEC endothelial cells (Fig. 6a–c; Supplementary Fig. 9c).
This was correlated with subcortical accumulation of F-actin
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Fig. 4 Phosphoproteomics elucidate downstream effectors of PI3Kα in endothelial cells. a Schematic illustration of the untargeted label-free mass
spectrometry analysis. The study was conducted in Pik3caflox/flox (control) and Pdgfb-iCre;Pik3caKD/flox (Pik3caKD/iΔEC) mouse lung endothelial cells under
exponential growing conditions upon preincubation with vehicle (EtOH) or 4-OHT for the indicated time points. The vehicle condition for analysis of the
heterozygous inactivation of PI3Kα (Pik3caKD/flox without induction of CRE activity) was included as a further control and four different mice were analysed
in each condition (a total of 24 samples). b Volcano plots exhibiting changes in phosphopeptides across genotypes. The Y axis represent the negative log10
of P value and the X axis shows the log2 of the fold change between control and Pik3caKD/iΔEC endothelial cells treated with vehicle (EtOH) for 24 h, 4-OHT
for 24 h or 4-OHT for 96 h. Red and yellow dots represent significantly regulated phosphopeptides (P < 0.01 and P < 0.05 respectively) with a fold-change
higher than 0.8 or lower than −0.8. c Venn diagram showing the number and percentage of phosphopeptides which are significantly upregulated or
downregulated between experimental groups. Number and percentage of overlapping phosphopeptides between groups are also shown. d Heatmap
indicating fold-changes in the phosphorylation of proteins related to the cytoskeleton. Phosphopeptides identified to be down- or upregulated in Pik3caKD/
iΔEC vs. Ctrl are shown in blue and red, respectively across EtOH and 4-OHT treatments. Values shown represent mean fold-change over Ctrl. e Western
blot validation of pS445 MYPT1 in mouse lung endothelial cells and HEK-293 cells upon genetic and pharmacological inhibition of PI3Kα. Control and
Pik3caKD/iΔEC endothelial cells were treated with 4-OHT for 72 h, re-platted for 24 h and subjected to immunoblotting. Wild-type endothelial cells and HEK-
293 cells were treated with vehicle or GDC-0326 for 48 h and subjected to immunoblotting. Quantification of at least three independent experiments is
shown in Supplementary Figure 8
si
Co
nt
ro
l
si
M
YP
T1
pS20 MLC2 F-actin β-catenin
pS20 MLC2 : F-actin
: β-catenin
c
MYPT1
pAKT(S473)
β-actin
GDC-0326– + – + – +
IP-IgG IP-MYPT1 Input
a
d
MYPT1
pS20 MLC2
siC
trl
siM
YP
T1
β-actin
b
**
Fo
ld
 c
ha
ng
e
pS20 MLC2
R
at
io
 o
f β
-
a
ct
in
 b
ou
nd
 to
 M
YP
T1 *
Fo
ld
 c
ha
ng
e
*
pS20 MLC2
Ve
hic
le
GD
C-0
32
6
150
37
50
50
20
150
0.0
0.5
1.0
1.5
0.0
0.5
1.0
1.5
2.0
2.5
0.0
0.5
1.0
1.5
2.0
2.5
siC
trl
siM
YP
T1
siC
trl
siM
YP
T1
(kDa) (kDa)
Fig. 5MYPT1 promotes dephosphorylation of MLC2 in endothelial cells. a Immunoblot analysis of HEK-293 cells treated with vehicle or GDC-0326 for 48
h using the indicated antibodies. Endogenous MYPT1 was immunoprecipitated and its ability to interact with actin was assessed in an overlay assay. Bars to
the right show quantification of actin bound to total MYPT1 from three independent experiments. b Western blot analysis of MYPT1, pS20 MLC2 and β-
actin in lysates of wild-type mouse lung endothelial cells transfected with siControl (siCtrl) or siMYPT1. Bars to the right show quantification of pS20 MLC2
normalized to β-actin from three independent experiments. c Images of endothelial cells transfected with siCtrl or siMYPT1, seeded on gelatin-coated
plates 72 h post-transfection, and immunostained for β-catenin (green), pS20 MLC2 (red) and F-actin (blue). d Quantification of total cell pS20 MLC2
immunostaining intensity (shown as integrated density) of images shown in c (n≥ 6 independent experiments). Scale bars, 15 µm (c). Data in a, b, and
d represent mean ± SEM (error bars). *P < 0.05, **P < 0.01. Statistical analysis was performed in a, and b by the two-sided Student’s t test and in d by the
two-sided Mann–Whitney test
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(Fig. 6a–c; Supplementary Fig. 9d). Instead, control cells showed
stress fibres evenly distributed between the cytoplasm and the
subcortical area of the cell (Fig. 6a–c). Analysis of Pik3caKD/iΔEC
retinal vessels confirmed an increase in the intensity of pS20
MLC2 (Fig. 6d, e) and F-actin staining (Fig. 6f, g). Together, these
experiments show that PI3Kα activity is required to downregulate
actomyosin contractility and may also explain why Pik3caKD/iΔEC
endothelial cells fail to stabilize junctions in vivo (Fig. 1).
NUAK1 inhibition restores PI3Kα-driven vascular phenotypes.
Two non-related protein kinases are able to phosphorylate
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Fig. 6 Inactivation of PI3Kα results in increased actomyosin contractility. a pS20 MLC2 (green), F-actin (red) and β-catenin (blue) immunostaining of
endothelial cells isolated from control and Pik3caKD/iΔEC mice treated with 4-OHT for 72 h and re-plated on gelatin-coated slides for 24 h. b Yellow islets
show higher magnification of selected regions in a. c Representative fluorescence intensities of pS20 MLC2, β-catenin and F-actin immunostaining
corresponding to the area depicted by the white line in b. Vertical blue arrows indicate endothelial junction between two endothelial cells. Punctuated lines
highlight subcortical area. d pS20 MLC2 (green) and IB4 (red) staining of control and Pik3caKD/iΔEC P7 retinas. e Quantification of the intensity of pS20
MLC2 staining per vascular area (shown as integrated density) (n≥ 5 retinas per genotype). f F-actin (green) and IB4 (red) staining of control and
Pik3caKD/iΔEC P7 retinas. g High magnification of selected regions shown in (f) illustrates the increase in F-actin intensity induced in Pik3caKD/iΔEC
endothelium. h Quantification of F-actin staining per vascular area (shown as integrated density) (n≥ 6 retinas per genotype). Scale bars, 15 µm (a), 20 µm
(d, f), 10 µm (g). Data in e and g represent mean ± SEM (error bars). *P < 0.05, **P < 0.01. Statistical analysis was performed by the two-sided
Mann–Whitney test
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MYPT1 on S445, namely NUAK family kinase 1 (NUAK1)35 and
large tumour suppressor kinase 1 (LATS1)37. Up to date, only
NUAK1 has been reported to regulate phosphorylation of
MLC235. Based on these findings, we tested whether restoring
MLCP activity by blocking NUAK1 reduces pS20 MLC2 and
suppresses actomyosin contractility. Treatment of endothelial
cells with a selective NUAK1 inhibitor (NUAKi)38 reduced
phosphorylation of MLC2 and F-actin staining (Fig. 7a). Inhibi-
tion of ROCK, the main kinase that phosphorylates MLC2, was
not sufficient to completely abrogate actomyosin contractility in
Pik3caKD/iΔEC endothelial cells (Supplementary Fig. 10a, b). In
contrast, ROCK inhibitor completely abrogated pS20 MLC2 and
disrupted stress fibres in control cells (Supplementary Fig. 10a, b).
This further supports the role of PI3Kα in the regulation of the
phosphorylation of MLC2 in an MYPT1/MLCP-dependent
manner.
Next, we attempted to rescue the vascular phenotypes triggered
by the inactivation of PI3Kα in vivo by treating newborn mice
with NUAKi. While inhibition of NUAK1 did not impact on the
outgrowth of the vasculature, it normalized the hyperbranched
vascular plexus and the vessel width and prevented the three-
dimensional growth in Pik3caKD/iΔEC retinas (Fig. 7c, d and
Supplementary Fig. 10c). In line with the observations in cultured
endothelial cells, administration of ROCK inhibitor in vivo did
not rescue the Pik3caKD/iΔEC retinal phenotype (Supplementary
Fig 10d-f). This further supports that PI3K signalling does not
regulate pMLC2 in a ROCK-dependent manner. Altogether, these
data demonstrate that regulation of the NUAK1/MYPT1/MLC2
axis by PI3Kα is required to inhibit actomyosin contractility in
cultured endothelial cells and in growing vessels in vivo (Fig. 7e).
Discussion
In this study, we present evidence demonstrating that the PI3K
downstream pathway, the NUAK1/MYPT1/MLCP axis, controls
actin dynamics in endothelial cells. We uncover that failure of
endothelial cells to rearrange results in vascular tubes composed
of stretched cells, which grow in a superimposed fashion and fail
to stabilize upon anastomosis. Our data support that a tight
regulation of endothelial cell movement, beyond tip cells, is
necessary for the adequate patterning of the vascular plexus. Cell
rearrangement is critical for any process that implies collective
cell migration such as in epithelial sheets and neural crest cells
during development, and in cancer cells during collective
invasion39,40. Thus, our discoveries may be translated to the
cellular and molecular dynamics orchestrating these critical
pathophysiological processes.
The combination of a PI3Kα-selective inhibitor together with
an endothelial-specific inducible genetic system has allowed us to
fully abrogate PI3Kα activity during vessel development and
unravel functions of this signalling hub. We show here that
inhibition of PI3Kα hinders endothelial cell pairing and triggers
defects in cell elongation. These aberrant cellular behaviours
ultimately result in stretches of unicellular vascular tubes devoid
of lumen. Thus, our data demonstrate that rearrangement of
endothelial cells is required to form well-organized, multicellular
vascular tubes. Our experimental strategies also reveal cell pro-
liferation defects in PI3Kα-inhibited endothelial cells. Although
it is possible that such defects contribute to the overall phenotype,
the observation that blockade of proliferation per se does
not interfere with junctional patterns argues for impaired junc-
tional remodelling and cell motility as an independent defect
in Pik3caKD/iΔEC retinas. Previous data showing that partial
decrease in PI3K output selectively decreases endothelial cell
migration with no defects in cell proliferation further support
this interpretation15,22. Pik3caKD/iΔEC retinas show an atypical
phenotype consisting of hyperbranching but reduced numbers of
endothelial cells. In contrast, canonical reduction of endothelial
cell proliferation in vivo, by over-activation of Notch or depletion
of VEGFR2, results in a hypobranched plexus41–43. Our data thus
highlight that increased numbers of branches is not always
associated with an increase in endothelial cell proliferation as
previously described. Taken together, the present data establish
that PI3Kα is an important regulator of sprouting angiogenesis
and confirm that angiogenic endothelial cells are exquisitely
regulated by this signalling hub.
Previous studies have described that PI3K signalling regulates
planar cell rearrangement in epithelial cells by stimulating junc-
tional lengthening and stability44,45. Our data show that inacti-
vation of PI3K signalling also impairs junctional remodelling in
cultured endothelial cells and identify that this also occurs during
vessel growth in vivo. Aberrant junctional patterns are indicative
of defects in cell rearrangements11. Therefore, this suggests that
cell rearrangement defects in our PI3Kα-inhibited in vivo models
are caused by impaired junctional remodelling. We also identify
that the spatial heterogeneity of junctional patterns required for
cells to rearrange is lost in Pik3caKD/iΔEC endothelial cells, with a
concomitant shift towards serrated immature junctions. While
current understanding of junctional patterns associates serrated
junctions with highly motile cells and straight junctions with
non-moving cells46, our data suggest that the loss of junctional
pattern heterogeneity, regardless of the type, blocks cell rearran-
gement. This agrees with previous results based on computational
models which indicate that cells rearrange when differential
adhesion strengths are found between neighbouring cells7.
Mechanistically, we show that PI3Kα mediates endothelial cell
rearrangement by inhibiting actomyosin contractility at the sub-
cortical edge of the cells. This is in line with previous reports
documenting that inactivation of PI3K in vitro leads to both
enhanced actin contractility47 and aberrant actin pattern48.
Together, this supports the notion that actomyosin activity has to
be low for cell rearrangements to occur. This is not unique of
endothelial cells as it has also been observed in Drosophila epi-
thelial tracheal tubes and in tumour cells49,50. Upon contraction,
the actomyosin machinery transmits force to cell−cell contacts
and regulates junctional remodelling12,50. This process is required
for cells to change their adhesion strengths and propel cell
movement. We observe that inhibition of PI3K impairs junction
stabilization and actomyosin contractility, and in turn reduces cell
migration. PI3K is at the crossroad of many extracellular inputs14;
thus it is not surprising that other mechanisms activate PI3K
signalling to stimulate endothelial cell migration during vessel
growth51. Indeed, during angiogenesis, fibronectin, a critical
component of the extracellular matrix of endothelial cells, med-
iates cell migration through the activation of PI3K51. Given that
aberrant adhesion of endothelial cells to the extracellular matrix
compromises the formation of stable adherent junctions in vivo52,
we speculate that the regulation of cell−cell adhesion and cell
−matrix adhesion by PI3K synergize to mediate cell rearrange-
ment during vessel growth.
The growth of the junctional ring upon establishing new
contacts is also impaired upon inactivation of PI3K in both
mouse retinas and in zebrafish embryos. This fits with the
observation that junctional elongation requires cortical tension
from the actomyosin cytoskeleton11,53. We postulate that during
angiogenesis, a tight equilibrium between stimulation and sup-
pression of actomyosin contractility is required to allow proper
growth of the newly formed junctional contact points. This also
explains why reduced phosphorylation of MLC2 is associated
with junctional defects in angiogenesis54,55. Together, our data
indicate that the regulation of junctional remodelling and stability
by PI3Kα signalling underscores changes in both cell−cell
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Fig. 7 Blockade of NUAK1 restores the endothelial phenotypes imposed by PI3Kα inactivation. a Confocal images of control and Pik3caKD/iΔEC endothelial
cells treated with 4-OHT for 72 h, re-plated on gelatin-coated slides for 24 h and treated with 10 μM WZ4003 (NUAK1 inhibitor; NUAKi) or DMSO as
control for 10min, and stained for pS20 MLC2, β-catenin and F-actin. b Quantification of subcortical pS20 MLC2 (upper graph) and F-actin (lower graph)
immunostaining intensities (shown as integrated density) (n≥ 14 images of three independent experiments). c IB4-stained control and Pik3caKD/iΔEC
retinas treated with DMSO as control or WZ4003 (NUAKi) at P6 (16:00), and isolated at P7 (1000 hours). d Quantification of branch points per unit area,
vessel width per unit area, and superimposed vascular tubes per unit area (n≥ 4 retinas per genotype and treatment). e Molecular mechanism by which
PI3Kα suppresses actomyosin contractility. Scale bars, 15 µm (a), 100 µm (c). Data in b and d represent mean ± SEM (error bars). *P < 0.05, **P < 0.01.
Statistical analysis was performed by the two-sided Mann–Whitney test
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adhesion properties and junctional growth upon new cell−cell
contacts. Given the similarity between the vascular defects in
Pik3caKD/iΔEC retinas and GDC-0326-treated zebrafish and those
observed in cdh5-mutant zebrafish embryos and mouse retinas,
we propose that PI3Kα and VE-cadherin cooperate to regulate
cell rearrangement and contact expansion.
We have identified a molecular pathway regulated by PI3K
signalling that points towards a role of PI3K in regulating actin
dynamics. Specifically, we have discovered that inactivation of
PI3Kα leads to enhanced phosphorylation of MYPT1 at S445, a
site which can be phosphorylated by NUAK1 (ref. 35). We
demonstrate that blocking NUAK1 restores both actomyosin
contractility and the vascular patterning defects triggered by
inactivation of PI3Kα In contrast, NUAKi does not restore the
outgrowth of the vasculature in Pik3caKD/iΔEC retinas. This might
be explained by the inability of NUAKi to restore endothelial cell
proliferation; thereby further supporting that cell rearrangement
defects and altered cell proliferation in Pik3caKD/iΔEC retinas are
two non-related events. At the moment, it is still not fully clear
how PI3K signalling inhibits NUAK1. Given that AKT inhibits
liver kinase B1 (LKB1) through phosphorylation-dependent
nuclear retention56 and LKB1 activates NUAK1, it is tempting
to speculate that PI3Kα blocks the ability of LKB1 to phosphor-
ylate NUAK1. By preventing the phosphorylation of MYPT1 on
S445 by NUAK1, PI3Kα then promotes MLCP phosphatase
activity (Fig. 7e). Supporting this idea, genetic endothelial
depletion of LKB1 opposes Pik3caKD/iΔEC vascular phenotypes,
with enhanced retinal angiogenesis and increased endothelial cell
proliferation and migration57. However, taking into account the
complexity of the PI3K signalling cascade, other pathways may
also contribute to the vascular defects seen in the Pik3caKD/iΔEC
vasculature.
Taken together, our study discovers the PI3Kα/MYPT1/MLCP
signalling axis as a critical hub in endothelial cell rearrangement
and highlights the key role of cell rearrangement in the orches-
tration of collective cell migration during angiogenesis. The reg-
ulation of actomyosin remodelling by PI3K signalling has been
observed in a variety of primary and tumour cells; yet the
molecular mechanism behind this regulation has not been fully
understood. Therefore, our findings may be translated into other
developmental and pathological situations.
Methods
Reagents. All chemicals, unless otherwise stated, were from Sigma-Aldrich.
Growing mediums for cultured cells were from Gibco.
Zebrafish. Maintenance of zebrafish (Danio rerio) and experimental procedures
involving zebrafish embryos were carried out at the Biozentrum/Universität Basel
according to Swiss national guidelines of animal experimentation (TSchV). Zeb-
rafish lines were maintained under licences 1014 H and 1014G1 issued by the
Veterinäramt-Basel-Stadt. The fish were maintained using standard procedures
and embryos obtained via natural spawning58, and embryos were staged by hours
post-fertilization (hpf) at 28.5 (ref. 59). All experiments were performed in accor-
dance with federal guidelines and were approved by the Kantonales Veterinäramt
of Kanton Basel-Stadt (Switzerland). The following zebrafish lines were used: Tg
(kdrl:EGFP-nls)ubs1 (ref. 29), Tg(fli1ep:mCherry-nls)ubs10 (ref. 60), Tg(kdrl:EGFP)
s843 (ref. 61), Tg(kdrl:mCherry-CAAX)s916 (ref. 62), and Tg(UAS:EGFP-UCHD)ubs18
(ref. 11). For pharmacological inhibition of PI3Kα, dechorionated zebrafish
embryos were treated with dimethylsulphoxide (DMSO) or 50 μM GDC-0326
inhibitor (Genentech23) in E3 medium supplemented with 0.003% 1-phenyl-2-
thiourea from 22 hpf or 27 hpf, as indicated in the Results section. E3 medium
containing DMSO or 50 μM GDC-0326 was changed every 4 h. To overcome
unspecified off-target effects induced by the combination of PI3Kα inhibitor and
laser exposure, all experiments were done in a p53 morpholino background. P53
morpholino (Gene Tools) was dissolved in DEPC water containing 0.2% phenol
red and 5 ng were injected to 1−2 cell-stage embryos. In order to block cell cycle
during angiogenesis63, 26−28 hpf zebrafish embryos were treated with 20 mM
hydroxyurea (HU) and 150 μM aphidicolin (APH). Embryo treatment lasted
throughout live imaging or until the embryos were fixed in 2 % PFA and prepared
for immunofluorescence.
Mice. Mice were maintained under specific pathogen-free conditions and kept in
individually ventilated cages. Experiments were conducted in accordance with the
guidelines and laws of the Catalan Departament d’Agricultura, Ramaderia i Pesca
(Catalunya, Spain) under the Project License number: DMAH 6809, following
protocols approved by the local Ethics Committees of IDIBELL-CEEA. All PI3Kα
mutant mice and littermate controls were bred in the C57/BL/6 genetic background
(Supplementary Table 1). For the analysis of angiogenesis in the postnatal mouse
retina, CRE-mediated recombination was induced in newborn mice by intraper-
itoneal (i.p.) injections of 25 µg of 4-OHT (2.5 µl of a 10 mgml−1 solution in
absolute ethanol) at P1 and P2. Eyes were harvested at P7 and P10 for analysis.
Control animals were littermate Pik3caflox/flox pups without CRE expression and
injected with 4-OHT. For mosaic inactivation of PI3Kα, R26-mTmG reporter
mouse31 was crossed with Pik3caKD/iΔEC mice and 0.8 µg of 4-OHT (2.5 µl of a
0.33 mgml−1 solution in absolute ethanol) was injected i.p. at P1, and eyes were
harvested at P7. CRE-mediated recombination was assessed by the expression of
membrane-bound GFP. Injected retinas from R26-mTmG;Pdgfb-iCreER;Pik3caflox/
WT mice were used as control for the analysis. The R26-mTmG allele was kept
heterozygous. To block proliferation, wild-type pups were i.p. injected with 10 μg g
−1 of animal of mitomycin C solution (Sigma, #M4287) as described in ref. 30 at P5.
At P7, all pups were i.p. injected with EdU (Invitrogen) to assess proliferation (EdU
staining protocol below). For pharmacological rescue experiment studies the fol-
lowing protocols were used: ROCK was inhibited in half of the pups from the same
litter by i.p. injection of 30 mg kg−1 of animal of Y-27632 (Calbiochem, #688000)
dissolved in DMSO at P6 (18:00) and P7 (10:00), and eyes were harvested at P7
(14:00). NUAK1 was inhibited in half of the pups by a single subcutaneous
injection of 30 mg kg−1 of animal of WZ4003 (Selleckchem, #S7317) at P6
(16:00 hours), and eyes were harvested at P7 (10:00). Control mice were injected
with DMSO only.
Cells. Mouse lungs were digested with Dispase (Life Technologies, #17105-041; 4
units ml−1) for 1 h at 37 °C, followed by positive selection with anti-mouse vascular
endothelial-cadherin (Pharmingen, #555289) antibody coated with magnetic beads
(Dynal Biotech, #110-35). Cells were seeded on a 12-well plate and were coated
with gelatin (0.5%) in DMEM/F12 supplemented with 20% foetal calf serum and
EC growth factor (PromoCell, #C30140) and 1% penicillin/streptomycin. After the
first passage, the cells were re-purified with vascular endothelial-cadherin antibody-
coated magnetic beads. Cells were cultured until passage 5. Human umbilical vein
endothelial cells (HUVECs, Lonza, #C2519A) were cultured in EBM-2 culture
medium supplemented with EGM-2 BulletKit (Lonza, #CC-3162) on 0.5% gelatin-
coated plates and culture up to passage 5. Human embryonic kidney cells (HEK-
293, ATCC, CRL-1573) were cultured in DMEM (Lonza, #12-733F) supplemented
with 10% of inactivated FBS and 1% penicillin/streptomycin. To induce gene
deletion in mouse lung endothelial cells 4-OHT (1 µM) or vehicle (ethanol) was
added to the cultured medium for 24 h, followed by replacing the medium without
4-OHT or vehicle. All the experiments were performed 96 h after the addition of 4-
OHT or vehicle. For pharmacological inhibition of ROCK and NUAK1 kinases,
cells were cultured for 24 h followed by treatment with vehicle (DMSO), 10 μM
ROCK inhibitor for 10 or 30 min, or 10 μM NUAK1 inhibitor for 10 min. For
pharmacological inhibition of PI3Kα, cells were treated with vehicle (DMSO) and
1 μM GDC-0326 inhibitor (Genentech) for 48 h.
siRNA transfection. Solution A (493 μl of Opti-MEM (Gibco, #51985026) with
7.5 μl of 20 μM control (Dharmacon, #D-001206-13) or 20 μM MYPT1 (Dhar-
macon, #M-063177-02 SMART pool siRNA oligomer)) and solution B (493 μl of
Opti-MEM with 7.5 μl of lipofectamine RNAi Max (Thermo Fisher Scientific,
#13778075)) were prepared and incubated for 5 min at room temperature (RT) in
separated tubes following the manufacturer’s instructions. Subsequently, solution B
was added to solution A and incubated for 20 min at RT, followed by adding A+ B
solution to endothelial cells (750,000 cells) in suspension resuspended in 500 μl of
Opti-MEM without antibiotics on cover-slips in six-well plates (three cover-slips
per well previously coated with 0.5% gelatin). The medium was changed the day
after, and cells were either fixed for immunofluorescence assays or lysed for wes-
tern blotting 72 h after transfection.
Protein extraction, immunoprecipitation and immunoblotting. Zebrafish
embryos were subjected to a deyolking protocol to avoid the interference of yolk
proteins in our analyses. Dechorionated embryos were collected in a 1.5 ml tube
filled with 1 ml deyolking buffer (55 mM NaCl, 1.8 mM KCl and 1.25 mM
NaHCO3). By pipetting with a narrow tip the yolk sac was disrupted. The embryos
were shaken for 5 min at 200 × g to dissolve the yolk. Cells were pelleted at 300 × g
for 30 s and the supernatant discarded. Two additional washes were performed by
adding 1 ml of wash buffer (110 mM NaCl, 3.5 mM KCl, 2.7 mM CaCl2, 10 mM
Tris/Cl pH 8.5), shaking 2 min at 200 × g and pelletting the cells as before. For
protein extraction, deyolked zebrafish embryos, mouse lung endothelial cells and
HEK-293 cells were lysed in 50 mM Tris HCl pH 7.4, 5 mM EDTA, 150 mM NaCl
and 1 % Triton X-100 supplemented with 2 mgml−1 aprotinin, 1 mM sodium
fluoride, 1 mM pepstatin, 1 ng ml−1 leupeptin, 1 mM phenylmethysulfonyl-
fluoridem, 10 g ml−1 Na-p-tosyl-L-lysine chloro-methyl ketone hydrochloride, 1
mM sodium orthovanadate, 1 μM okadaic acid and 1 mM DTT followed by
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clearance of lysates by centrifugation. Supernatants were resolved on 8, 10 or 12%
SDS–PAGE gels, transferred onto nitrocellulose or PVDF membranes. Membranes
were blocked in 5% (w/v) skimmed milk, incubated with specific primary anti-
bodies overnight at 4 °C in 2% BSA in 0.1% Tween-20 TBS buffer (further referred
to as TBST), then washed three times with TBST and incubated with peroxidase-
conjugated secondary antibodies in 5% (w/v) skimmed milk in TBST at RT for 1 h.
The following primary antibodies were used: p-AKT (Ser 473) (Cell Signaling
Technology, #4060, diluted 1:1000), AKT (Cell Signaling Technology, #9272,
diluted 1:2000), VE-cadherin (Santa Cruz Biotechnology, #sc-6458, diluted 1:500),
p85 (Millipore, #ABS234, diluted 1:2000), PI3Kα (monoclonal clone U3A64),
Ser445 MYPT1 (MRC Reagents, #S508C35, 1 μg ml−1), MYPT1 (MRC Reagents,
#S110D, ref. 35, 1 μg ml−1 with a 10 μg ml−1 of a dephosphopeptide variant of the
antigen used to raise the antibody), pS19/S20 MLC2 (Rockland Antibodies,
#039600-401-416, diluted 1:500), β-actin (Abcam, #ab49900, diluted 1:10,000) and
α-tubulin (Sigma-Aldrich, #T6074, diluted 1:10,000). The following secondary
antibodies from DAKO were used in a 1:5000 dilution: swine anti-rabbit (#P0399),
rabbit anti-goat (#P0449), rabbit anti-mouse (#P0260), and rabbit anti-sheep
(#P0163).
MYPT1 immunoprecipitation (IP) was performed using a sheep polyclonal
MYPT1 antibody (MRC Reagents, #S110D) covalently coupled to protein G-
Sepharose (GE Healthcare, #17-0618-01) (1 μg of antibody per 1 μl of beads) with a
dimethyl pimelimidate cross-linking procedure35. Cells treated with DMSO or
GDC-0326 for 48 h were lysed with IP buffer (50 mM Tris pH 8.0, 150 mM NaCl,
0.1% SDS, 1% NP40, 0.5% sodium deoxycolate, 2 mg ml−1 aprotinin, 1 mM
pepstatin A, 1 ng ml−1 leupeptin, 10 g ml−1 TLCK, 1 mM PMSF, 1 mM NaF, 1 mM
NaVO3 and 1 μM okadaic acid) and clarified by centrifugation at maximum speed
for 15 min at 4 °C. Cell lysate (1 mg) was incubated with 5 μg of coupled antibody
for 1 h at 4 °C. Immunoprecipitates were washed four times with IP buffer and
resuspended in 1× SDS Sample Buffer. Immunoprecipitates and cell lysates (50 μg)
were subjected to electrophoresis on 8−12% SDS–PAGE and transferred to
nitrocellulose membranes. For sheep antibodies, the membranes were incubated for
30 min with TBST containing 10% (w/v) skimmed milk. The membranes were then
immunoblotted in 10% (w/v) skimmed milk in TBST with the MYPT1 primary
antibody (1 μg ml−1) overnight at 4 °C. The incubation with phosphospecific
MYPT1 sheep antibody was performed with the addition of 10 μg ml−1 of a
dephosphopeptide variant of the antigen used to raise the antibody. Uncropped
scans are shown in Supplementary Figures 11-13.
Live 2D wound healing assay. Mouse lung endothelial cells and HUVECs were
plated on six-well plate dishes coated with 0.5% gelatin to grow to confluence for
24 h. Cell monolayers were scratched with a p200 pipette tip to induce cell
migration. Phase-contrast images were performed every 10 min using a widefield
microscope (NIKON Eclipse TI) equipped with a ×10air objective and an Andor
Zyla 4.2 plus sCMOS camera. An Okolab cage incubator and humidified CO2 gas
chamber set to 37 °C and 5% CO2 were used during the imaging process.
Immunofluorescence analysis in zebrafish, retinas and cells. For immuno-
fluorescence and imaging of zebrafish embryos, dechorionated zebrafish embryos
were fixed in 2% paraformaldehyde and 0.1% Tween 20 in PBS overnight at 4 °C.
After fixation, embryos were washed four times with 0.1% Tween 20 in PBS
(hereafter refer to as PBST) for 5 min, permeabilized with 0.5% Triton-X-100 in
PBS at room temperature (RT) for 15−30 min, and blocked with 1% BSA, 5% goat
serum (Gibco, #16210-064) and 0.2% Triton X-100 in PBS at 4 °C overnight by
continuous shaking. Thereafter, embryos were incubated with mouse anti-human
ZO-1 (Zymed, #33-9111, diluted 1:200) in 500 μl of blocking buffer at 4 °C over-
night, washed in PBST at least six times for over 3 h, and incubated with Alexa-633
goat anti-mouse IgG (Invitrogen, #A-21053, diluted 1:1000) in 500 μl of blocking
buffer overnight at 4 °C. Embryos were finally washed in PBST at 4 °C overnight
with continuous shaking. Fixed or live fluorescence positive zebrafish embryos were
selected using a Leica MZ FLIII fluorescent, anaesthetized in E3 supplemented with
1× tricaine pH 7 (0.08%) and mounted in a 35 mm glass-bottomed dish (0.17 mm;
MatTek), using 0.7% low melting agarose containing 1× tricaine. For live imaging,
the mounting agarose was additionally supplemented with 0.003 % phenylthiourea
(PTU) and inhibitor if the case.
Mouse eyes were fixed in 4% PFA in PBS for 1 h on ice and washed in PBS for at
least 10 min. Retinas were isolated and fixed with 4% PFA in PBS for 1 h on ice.
After washing the retinas with PBS three times, they were incubated with blocking
buffer (1% BSA, 0.3% Triton X-100 in PBS) overnight at 4 °C. Then, retinas were
incubated with the specific primary antibodies diluted in blocking buffer overnight
at 4 °C. Primary antibodies against the following proteins were used: pSer240/244-
S6 (Cell Signaling Technology, #2215, diluted 1:100), FOXO1 (Cell Signaling
Technology, #2880S, diluted 1:100), VE-cadherin (BD Bioscience, #555289, diluted
1:50), ERG (Abcam, #AB92513, diluted 1:400), Collagen IV (Chemicon
international, #AB756P, diluted 1:50), ICAM-2 (BD Bioscience, #553326, diluted
1:100), pS19/S20 MLC2 (Rockland Antibodies, #039600-401-416, diluted 1:100).
Retinas were washed three times in PBST and then in Pblec buffer (1% Triton X-
100, 1 mM CaCl2, 1 mM MgCl2 and 1 mM MnCl2 in PBS, pH 6.8) for 30 min at
RT. Thereafter the retinas were incubated for 2 h at RT or overnight at 4 °C in
Pblec buffer containing Alexa-conjugated secondary antibodies (diluted 1:200) and
Alexa-conjugated Isolectin GS-B4 (IB4, Invitrogen, #I21411, #I21412, I32450,
diluted 1:300), washed three times with PBST and flat-mounted on microscope
glass slides with Mowiol (Calbiochem, #475904). For F-actin staining, Alexa-Fluor
568-conjugated phalloidin (Invitrogen, #A12380, diluted 1:400) was used. The
following secondary antibodies Alexa-Fluor conjugated were used (1:300 dilution):
Alexa-Fluor 488 goat anti-rat (Invitrogen, #A11006), Alexa-Fluor 488 goat anti-
rabbit (Invitrogen, #A11008), Alexa-Fluor 568 goat anti-rabbit (Invitrogen,
#A11011), Alexa-Fluor 647 donkey anti-rabbit (Invitrogen, #A31573). The
labelling of proliferative endothelial cells with EdU was performed at P7. Pups were
injected i.p. with 60 μl of EdU (0.5 mgml−1 in PBS, Invitrogen, #C10340) 2 h
before they were sacrificed. EdU-positive cells were detected in the retinal
vasculature with the Click-iT EdU Alexa Fluor-647 Imaging Kit (Invitrogen,
#C10340).
Endothelial cells were seeded on cover-slips in six-well plates coated with 0.5%
gelatin. 24 h later, corresponding treatment was done and cells were washed once
with cold PBS (supplemented with 1 mM CaCl2 and 0.5 mM MgCl2) and fixed in
4% PFA for 15 min at RT. Cells were then washed with PBS and permeabilized in
0.1% Triton X-100 in PBS for 30 min at RT and incubated in blocking solution (3%
BSA, 5% goat serum, 0.1% Triton X-100 in PBS) for 1 h at RT. Cover-slips were
removed from the culture plate and were incubated in the appropriate dilution of
primary antibodies in blocking solution ON at 4 °C in a wet chamber. Primary
antibodies against the following proteins were used: pS19/S20 MLC2 (Rockland
Antibodies, #039600-401-416, diluted 1:100) and β-catenin (BD Bioscience
#610153, diluted 1:200). The following day, cover-slips were washed three times
with PBS at RT and incubated in the appropriate dilution of Alexa-Fluor 488 goat
anti-rabbit (Invitrogen, #A11008, diluted 1:200), Alexa-Fluor 568 goat anti-mouse
(Invitrogen, #A21236, diluted 1:200) and Alexa-Fluor 633-conjugated phalloidin
(Invitrogen, #A22287, diluted 1:400) in PBS for 2 h at RT in a wet chamber. Three
washes with PBS were performed, adding 1 μg ml–1 of 4′,6-diamidino-2-
phenylindole (DAPI; Molecular Probes, #D1306) in the last one.
Imaging analysis and quantification. All quantifications obtained from confocal
(Leica SP5) or widefield microscopes (Nikon Eclipse 80i or Nikon Eclipse TI) were
performed using Image J software (http://fiji.sc/). Zebrafish movies were analysed
with ImageJ software. Photoshop and Illustrator (Adobe) software were used for
image processing.
In the zebrafish, images were taken at ×40(NA= 1.1) water immersion
objective, maximum intensity projections were used for quantification and five
ISVs were quantified per embryo. Measurements of ISVs length were made straight
from the edge of the aorta to the leading edge of the sprout and the number of
endothelial nuclei in that length was quantified. The number of endothelial nuclei
in the DLAV and DA was quantified per segment within five ISVs. Junctional
length and junctional gaps length were measured in embryos stained for ZO-1.
Only flat-mounted embryos were selected for quantification avoiding crooked ones.
In the retina, vascular parameter were quantified in at least four images of
comparable vascular areas per retina and of at least three mice of each genotype or
experimental conditions. All images shown in the figures are maximum intensity
projections unless otherwise specified. For the quantification of retinal vessel
progression overview, widefield images of IB4-stained retinal vasculature were
obtained with the ×10 objective (Nikon Eclipse 80i microscope). The distance of
vessel growth from the centre of the optic nerve to the edge of the angiogenic front
was measured per each retina leaflet. The mean of all leaflet measurements was
obtained per retina and compared between control and mutant groups. For all
other quantifications high-resolution confocal images at ×40 oil immersion
objective was used. The number of filopodia and sprouts were quantified at the
angiogenic front. The total number of filopodia and sprouts were normalized to a
vessel length of 100 μm at the angiogenic front. Endothelial branch points, vessel
width, superimposed vascular tubes, number of junctional gaps, length of
junctional gaps, distance between nuclei, endothelial cell numbers, collagen IV
empty sleeves and lumen disconnections were quantified behind the angiogenic
front in fields sized 100 μm× 100 μm. For quantification of cell shape, single GFP-
positive cells located behind the sprouting front were only considered. Vessel
width, distance between neighbouring cells, length of junctional gaps and area of
GFP-positive cells was determined using ImageJ software with the proper scale set
up. To assess the proliferation rate, double-positive EdU/ERG endothelial nuclei
were counted in field of 200 μm× 200 μm behind the vascular sprouting front and
the total number was divided by the total number of endothelial cells (ERG-
positive nuclei). For quantification of pS20 MLC2 and F-actin immunostaining,
signal intensity within IB4 positive area in images taken with the ×40 oil immersion
objective was measured. In brief, manual threshold was set to obtain binary images
of IB4 staining. IB4-positive area was measured and defined as a region of interest
(ROI). Integrated density of pS20 MLC2 or F-actin was measured in the IB4-
positive area for each image. Then, to calculate the corrected total fluorescence
(CTF), the following formula was used: CTF= Integrated Density – (Area selected
for IB4 positivity ×Mean fluorescence of background readings). The background
readings were taken from three areas close to the vasculature but negative for IB4.
3D reconstructions were generated by using the Leica LAS-X.
In phase-contrast wound healing assays, quantification of cell migration was
made by measuring the percentage of cell-free area. Cells from the first, second and
third row were manually tracked using the Manual Tracking plugin and cell
velocity, directionality and travelled distance were calculated with the chemotaxis
tool plugin.
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In cultured endothelial cells, maximum intensity projections of confocal images
with the ×63 oil immersion objective were acquired. Signal intensity of pS20 MLC2
and F-actin immunostaining/cell was quantified using the junctional staining of β-
catenin to select individual endothelial cells (ROI A1). Using the enlarge command
two concentric areas were drawn in each cell (distance of −2.5 μm (ROI A2) and
−7.5 μm (ROI A3) from the junctional β-catenin positive staining). Integrated
density was measured. For measuring total intensity levels: area from ROIs A1 was
used as templates to measure total integrate intensity of pS20 MLC2 and F-actin
staining in individual endothelial cells. For measuring subcortical levels: Integrate
density from ROIs A2 to ROI A3 was calculated in individual endothelial cells. The
mean of the integrate density of four cells per image, and at least four images per
genotype and treatment were used for the quantification. β-catenin junctional
positive area/cell perimeter was calculated per individual cell. For that, a manual
threshold was set to obtain binary images. Then, total β-catenin area—β-catenin
nuclear area in individual cells was calculated to obtain β-catenin junctional
positive area. Junctional staining of β-catenin was used to measure the perimeter of
individual cells. At least four cells per image and four images per genotype were
used for the quantification. To measure the type of junctional coverage, percentage
of junctional pattern was considered. ≥60% serrated pattern/cell= serrated, ≥ 60%
of straight junctional pattern/cell= straight, ≈50% of each pattern/cell=mixed.
Five cells per image and at least five images per genotype were used for the
quantification.
Mass spectrometry. Primary endothelial cells were washed twice with cold PBS
supplemented with 1 mM Na3VO4 and 1 mM NaF and lysed with 300 µl of urea
buffer (8 M Urea in 20 mM in HEPES pH 8.0 supplemented with 1 mM Na3VO4, 1
mM NaF, 1 mM Na4P2O7 and 1 mM sodium β-glycerophosphate) for 30 min. All
mass spectrometry solvents were prepared in LC-MS grade water (LGC Pro-
mochem, #SO-9368-B025). We used published methods for phosphoproteome
analyses32,65,66. In brief, 250 µg of protein were reduced and alkylated by sequential
incubation with 10 mM DTT and 16.6 mM iodoacetamide for 1 h. Urea con-
centration was diluted to 2M with 20 mM HEPES (pH 8.0), and 80 µl of trypsin
beads (50% slurry of TLCK-trypsin (Thermo-Fisher Scientific, #20230)) pre-
conditioned with three washes of 20 mM HEPES (pH 8.0) were added to the
samples, followed by incubating the tubes for 16 h at 37 °C with agitation. Trypsin
beads were removed by centrifugation at 2000 × g for 5 min at 5 °C. Following
trypsin digestion, peptide solutions were desalted using 10 mg OASIS-HLB car-
tridges (Waters, #186000383). Briefly, OASIS cartridges were accommodated in a
vacuum manifold (−5 mmHg), activated with 1 ml ACN (LGC Promochem, #SO-
9340-B025) and equilibrated with 1.5 ml of washing solution (1% ACN, 0.1% TFA
(LGC Promochem, #SO-9668-B001)). After loading the samples, cartridges were
washed with 1 ml of washing solution. Phosphopeptides were eluted with 500 µl of
glycolic acid buffer 1 (1 M glycolic acid (Acros Organics, #154515000), 50% ACN,
5% TFA) and subjected to phosphoenrichment. Phosphopeptides were enriched
using TiO2 (GL Sciences, #5020-75010). Sample volumes were normalized to 1 ml
using glycolic acid buffer 2 (1M glycolic acid, 80% ACN, 5% TFA), 50 µl of TiO2
beads (50% slurry in 1% TFA) were added to the peptide mixture, incubated for 5
min at RT with agitation and centrifuged for 30 s at 1500 × g. For each sample, 80%
of the supernatant was transferred to fresh tubes and stored in ice and the
remaining 20% used to resuspend the bead pellets that were loaded into an empty
prewashed PE-filtered spin-tips (Glygen, #TF2EMT.96) and packed by cen-
trifugation at 1500 × g for 3 min. After loading the remaining volume of the
supernatant by centrifugation at 1500 × g for 3 min, spin tips were sequentially
washed with 100 µl of glycolic acid buffer 2, ammonium acetate buffer (100 mM
ammonium acetate in 25% ACN) and 10% ACN by RT centrifugation for 3 min at
1500 × g. For phosphopeptide recovery, additional 50 µl of 5% ammonia solution
(LGC Promochem, HPA-0070-B010) followed by centrifugation for 5 min at
1500 × g was repeated four times. Eluents were snap frozen in dry ice, dried in a
speed vac (RVC 2-25, Martin Christ Gefriertrocknungsanlagen GmbH, Osterode
am Harz, Germany) and peptide pellets stored at −80 °C. Peptide pellets were
resuspended in 12 µl of reconstitution buffer (20 fmol/µl enolase (Waters,
#186002325) in 3% ACN, 0.1% TFA) and 5 µl were loaded onto an LC-MS/MS
system consisting of a Dionex UltiMate 3000 RSLC directly coupled to an Orbitrap
Q-Exactive Plus mass spectrometer (Thermo Fisher Scientific). Peptides were
trapped in a μ-pre-column (Acclaim PepMap 100, Themo Fisher Scientific,
#160454) and separated in an analytical column (Acclaim PepMap 100, Thermo
Fisher Scientific, #164569) using A (3% ACN, 0.1% FA (Thermo Fisher Scientific, #
F-1850-PB08)) and B (100% ACN, 0.1% FA) solutions as mobile phases. The
following parameters were used: 3−23% B gradient for 120 min and a flow rate of
0.3 µl min−1. As they eluted from the nano-LC system, peptides were infused into
the online connected Q-Exactive Plus system operating with a 2.1 s duty cycle.
Acquisition of full scan survey spectra (m/z 375−1500) with a 70,000 FWHM
resolution was followed by data-dependent acquisition in which the 20 most
intense ions were selected for HCD (higher energy collisional dissociation) and
MS/MS scanning (200−2000 m/z) with a resolution of 17,500 FWHM. A 30 s
dynamic exclusion period was enabled with an exclusion list with 10 ppm mass
window. Overall duty cycle generated chromatographic peaks of approximately 30
s at the base, which allowed the construction of extracted ion chromatograms
(XICs) with at least ten data points.
Peptide identification and quantification. Mascot Daemon 2.5.0 was used to
automate peptide identification from MS data. Peak list files (MGFs) from RAW
data were generated with Mascot Distiller v2.5.1.0 and searched into the Mascot
search engine (v2.5) in order to match MS/MS data to theoretical peptide frag-
mentation data67. The searches were performed against the SwissProt Database
(uniprot_sprot_2014_08.fasta) with an FDR of 1% (specific FDR for each phos-
phopeptide identification is included in Supplementary Data 1). A maximum of 2
trypsin missed cleavages and a mass tolerance of ±10 ppm for the MS scans and ±
25 mmu for the MS/MS scans were allowed. Carbamidomethyl Cys as fixed
modification, and phosphorylation at Ser, Thr, and Tyr, PyroGlu on N-terminal Gln
and oxidation of Met as variable modifications were considered. The accuracy of
phosphosite location within the identified peptides was assessed using delta score
values as described by Savitski et al.68. Delta scores for each phosphopeptide are
reported in Supplementary Data 1. In-house developed software (Pescal) was used
for label-free peptide quantification69. Pescal constructs extracted ion chromato-
grams (XIC) for each identified peptide and measures the area of the XICs for all the
peptides identified across all samples. Thresholds for XIC generation were ±7 ppm
and ±2min m/z and retention time windows, respectively and undetectable peptides
were given an intensity value of 0. Values of two technical replicates per sample
were averaged and intensity values for each peptide were normalized to total sample
intensity. Normalized quantitative data were used to calculate fold changes between
groups and statistical significance (assessed by Student’s t test) when necessary. The
construction of volcano plots and heatmaps was automated with a script generated
in R software using the ggplot package. Venn diagrams were constructed using the
software Venny (v2.1, http://bioinfogp.cnb.csic.es/tools/venny).
Statistics. Data were analysed using GraphPad Prism software and were presented
as mean ± SEM (error bars). Sample size and experimental replicates were indi-
cated in figure legends. Statistical analysis was performed by the nonparametric
Mann−Whitney’s test or the parametric Student’s t test. ns not significant; *P <
0.05; **P < 0.01; ***P < 0.001; and ****P < 0.001 were considered statistically
significant.
Code availability. The mass spectrometry data is deposited in the PRIDE repo-
sitory (www.ebi.ac.uk/pride/archive/) with the dataset identifier PXD007060. The
codes used for analysing the mass spectrometry data are annotated in Supple-
mentary Table 2.
Reporting Summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The mass spectrometry data that support the findings of this study have been
deposited and are publicly available at the ProteomeXchange Consortium via the
PRIDE70 partner repository (www.ebi.ac.uk/pride/archive/) with the dataset iden-
tifier PXD007060. The rest of the data and materials generated within this study are
available from the corresponding author upon request. A reporting summary for
this article is available as a Supplementary Information file.
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